Orion Portfolio Solutions LLC Has $1.42 Million Stake in Insulet Co. (NASDAQ:PODD)

Orion Portfolio Solutions LLC reduced its position in shares of Insulet Co. (NASDAQ:PODD) by 30.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 5,453 shares of the medical instruments supplier’s stock after selling 2,373 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Insulet were worth $1,424,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Pictet Asset Management Holding SA boosted its position in shares of Insulet by 14.6% in the fourth quarter. Pictet Asset Management Holding SA now owns 41,989 shares of the medical instruments supplier’s stock valued at $10,962,000 after acquiring an additional 5,353 shares during the period. Boussard & Gavaudan Investment Management LLP acquired a new stake in shares of Insulet in the fourth quarter valued at approximately $2,036,000. New Age Alpha Advisors LLC acquired a new stake in shares of Insulet in the fourth quarter valued at approximately $7,857,000. Norges Bank bought a new stake in shares of Insulet in the fourth quarter valued at approximately $248,806,000. Finally, UniSuper Management Pty Ltd grew its position in Insulet by 9.6% during the fourth quarter. UniSuper Management Pty Ltd now owns 8,717 shares of the medical instruments supplier’s stock worth $2,276,000 after buying an additional 765 shares in the last quarter.

Insulet Stock Performance

Shares of PODD stock opened at $256.80 on Friday. The firm has a market capitalization of $18.03 billion, a price-to-earnings ratio of 44.35, a PEG ratio of 3.62 and a beta of 1.29. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The business’s 50-day moving average price is $270.56 and its 200-day moving average price is $259.45. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Equities research analysts forecast that Insulet Co. will post 3.92 EPS for the current year.

Insider Buying and Selling

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now directly owns 3,231 shares of the company’s stock, valued at approximately $888,525. The trade was a 36.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PODD. Wells Fargo & Company upped their target price on Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. TD Cowen upped their price objective on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. StockNews.com lowered shares of Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Citigroup upped their price target on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Finally, Royal Bank of Canada began coverage on shares of Insulet in a research report on Thursday, March 6th. They set an “outperform” rating and a $340.00 price objective for the company. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $292.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.